GitHub's COO shared this under-reported X post last month [1] on their exponential growth. I'd love to see more proactive messaging on their growth rate / vision for agentic interactions.
> … platform activity is surging. There were 1 billion commits in 2025. Now, it's 275 million per week, on pace for 14 billion this year if growth remains linear (spoiler: it won't.)
> GitHub Actions has grown from 500M minutes/week in 2023 to 1B minutes/week in 2025, and now 2.1B minutes so far this week.
I have "Advanced Protection" turned on, so I just can't use this at all, because my newly created Google Cloud GCP app isn't trusted (even though I own it and I'm requesting read-only scopes). What a mess.
Access blocked: [app name] is not approved by Advanced Protection. Error 400: policy_enforced
I found the most interesting part of the NIST outage post [1] is NIST's special Time Over Fiber (TOF) program [2] that "provides high-precision time transfer by other service arrangements; some direct fiber-optic links were affected and users will be contacted separately."
I've never heard of this! Very cool service, presumably for … quant / HFT / finance firms (maybe for compliance with FINRA Rule 4590 [3])? Telecom providers synchronizing 5G clocks for time-division duplexing [4]? Google/hyperscalers as input to Spanner or other global databases?
Seriously fascinating to me -- who would be a commercial consumer of NIST TOF?
I was optimistically hoping some of the MV3 changes would result in Chrome webstore policy enforcement being standardized, but that hasn't happened.
Sensor Tower (https://sensortower.com/) makes a lot of popular extensions, like StayFocusd https://www.stayfocusd.com/. They seem to resell ad data (in violation of [1]?) and ship likely obfuscated code [2] (in violation of [3]?), but there's no enforcement or even clear reporting mechanism.
Agreed! This specifically is for adjuvant osimertinib for EGFR+ Stage IB–IIIA completely resected NSCLC.
The headline here is really strong -- and the actual abstract is much more sober: "5-year OS rate was 88% with osimertinib vs 78% with placebo" [Full abstract is here: https://meetings.asco.org/abstracts-presentations/219805 ]
P.S. Hi Chris! (I think I picked up a summer student from you last week!)
Oberlin has an endowment valued at approximately $1 billion — this is ~3% of that. (Understanding all those funds may not be liquid, they certainly have some assets.)
Carbon costs per-vehicle can be calculated based on your local grid power source, duration of ownership, and more: https://www.carboncounter.com/ -- be sure to click the "Customize" tab
If your annual driving distance is low (<5,000 miles) and your grid is relatively dirty (e.g. the midwest [SRMW] grid), a range of EVs have more CO2 emissions/mile than conventional internal combustion vehicles.
Physician scientist here: this study is a bit dated. Many of these issues have been "solved" (depending on your threat model) within the last ~7 years. Most healthcare systems have adopted Imprivata [1] for SSO, where physicians tap a badge and are connected to (usually) a VDI session of Epic.
What this study misses is the real driver of EMRs: billing. EMRs exist to facilitate billing documentation to charge for patient care. Yes, they have other benefits (like viewing lab results), but if you ever see true critical care (at the bedside, in an ER, or in an ICU) little depends on the EMR (or even labs for that matter).
A few comments here talk about patient notes: in most clinical environments, inpatient notes are useless, and a tedium required to bill. They're filled with copy-pasted jargon to meet insurance company requirements. True patient care happens in less than ~1 paragraph of text called a handoff. [2]
The lack of a stockpile is due to limited shelf stability and long-term bacterial growth.
It's unfortunate Reason doesn't expand on the other side of this issue: the formula industry lobbied the FDA to reduce bacterial testing frequency (and inspections overall), with an emphasis on Cronobacter risks, arguing that the FDA "overestimat[ed] the expected annual incidence of Cronobacter infection". [1]
Hey Graham -- great post! The Medtronic / Guardian sensor combo is generally disliked by patients, though (in the US) the Medtronic 770G is FDA approved for ages 2+.
The bleeding edge is the Beta Bionics (https://www.betabionics.com/) bi-hormonal system (insulin + glucagon), currently in clinical trials for ages 6+.
This builds on an NHTSA-funded pilot program called Driver Alcohol Detection System for Safety (DADDS; https://www.dadss.org/).
DADDS advanced two technologies for passive impaired driving detection: non-contact breath sensors (exhaled EtOH near the driver), and touch sensors (embedded into the steering wheel).
The bill adds this as a requirement on top of existing distracted driving prevention systems, which have been expanding but don't always get much press (e.g. Subaru's driver-facing cameras).
The mechanisms of parthonenogensis aren't fully characterized, but at a high level, it occurs in a secondary oocyte during meiosis II -- the oocyte only starts out with a Z or W chromosome.
Physician scientist here -- this is a unique and somewhat odd case where Martha prefers to use the iron lung over modern alternatives.
She would likely do fine with a modern non-invasive positive pressure ventilation (NIPPV) approach.
There are many patients with other illnesses (COPD, ALS, etc.) that depend on nocturnal ventilation -- most commonly nocturnal BiPAP (two pressure levels that support respiratory muscles).
Physician here; this isn't true for the ventilation of COVID patients, or ICU patients in general.
There's a difference between simple ventilator [1], and an anesthesia machine [2] that adds gas mixing, scavenging, etc.
ICU patients are anesthetized using IV sedation (a common regimen in the US is fentanyl/propofol), not inhalational anesthetics. Most vents only have simple inline filters to reduce contamination.
Probably because most data disagree with this comment. There's a ~20% relative risk reduction in vascular events & mortality per ~40 mg/dL decrease in LDL.
> … platform activity is surging. There were 1 billion commits in 2025. Now, it's 275 million per week, on pace for 14 billion this year if growth remains linear (spoiler: it won't.)
> GitHub Actions has grown from 500M minutes/week in 2023 to 1B minutes/week in 2025, and now 2.1B minutes so far this week.
[1] https://x.com/kdaigle/status/2040164759836778878